台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

(MP1-8) Allyl isothiocyanate up-regulates miR-30a-5p expression through a ROS responsive transcription factor, activator protein 1 (AP-1)

2016-12-20 • 觀看: 2560 • 回應: 0 • doc
(MP1-7) Outcome of second-look transurethral resection bladder tumor for superficial t1 bladder cancer - chi mei medical center experience

2016-12-20 • 觀看: 2554 • 回應: 0 • doc
(MP1-6) Bladder instillation with mitomycin or bacillus calmette-guérin in patients of non muscle invasive bladder cancer: eight years experiences

2016-12-20 • 觀看: 2569 • 回應: 0 • doc
(MP1-5) Impact of metastasectomy on metastatic renal cell carcinoma treatment---experience of taichung veterans general hospital

2016-12-20 • 觀看: 2497 • 回應: 0 • doc
(MP1-4) Factors affect quality of life in patients with renal and upper urinary tract carcinoma after surgery in Taiwan: a preliminary report

2016-12-20 • 觀看: 2778 • 回應: 0 • doc
(MP1-3) Inhibition of cisplatin-induced autophagy by overexpression of miR-30a-5p

2016-12-20 • 觀看: 2576 • 回應: 0 • doc
(MP1-2) Sequential treatment of metastatic renal cell carcinoma with targeted therapy---experience of taichung veterans general hospital

2016-12-20 • 觀看: 2614 • 回應: 0 • doc
(MP1-1) The incidence and management of lymphoceles after robotic-assisted laparoscopic radical prostatectomy

2016-12-17 • 觀看: 2804 • 回應: 0 • doc
(MP6-10) Retrospective Analysis of Preoperatively PI-RADS score and of Post-Operative Pathological Report inPatients of Prostate Cancer without Preoperative Proof

2016-08-03 • 觀看: 5 • 回應: 0 • ppt
(MP6-9) CAPSAICIN INDUCES APOPTOSIS AND CELL CYCLE ARREST IN BLADDER CANCER TSGH-8301 CELLS

2016-08-03 • 觀看: 3 • 回應: 0 • ppt
(MP6-8) THE CLINICAL EFFICACY OF NEOADJUVANT CHEMOTHERAPY ON UROTHELIAL CARCINOMA OF THE BLADDER: A RETROSPECTIVE ANALYSIS FROM A SINGLE-CENTER IN TAIWAN

2016-08-03 • 觀看: 2 • 回應: 0 • ppt
(MP6-6) Mammalian Target of Rapamycin Inhibitor and Transarterial Embolization of Tuberous Sclerosis Complex-associated Renal Angiomyolipoma: A Case Series

2016-08-03 • 觀看: 2 • 回應: 0 • ppt